SummaryResearcher Dave Kuszmar discovered multiple systemic vulnerabilities that let him bypass LLM safety and obtain dangerous instructions. These exploits worked across nearly all major LLMs ...
Welcome to Electronic Design's weekly publication, where you can find the latest articles, videos, and podcasts. All too often, the rapid changes, even on this website, cause information to disappear ...
CINCINNATI (WKRC) - After a decade of work, a student-built research satellite is set to be deployed on Thursday morning, months after it was launched to the International Space Station. The project ...
Beijing, China-based Meituan Inc. today debuted its next-generation LongCat-2.0 open-source large language model, stating that the company trained the 1.6-trillion-parameter model on domestic Chinese ...
George Gianarikas, Canaccord Genuity analyst, joins 'The Exchange' to discuss concerns around over-investment in AI, the impact of power demand changes and much more. Got a confidential news tip? We ...
LakeFusion MDM is now available as a Databricks App, letting customers install and deploy governed master data management directly within their Databricks environment Databricks Data + AI Summit, June ...
June 10 (Reuters) - Microsoft (MSFT.O), opens new tab is limiting employees' use of Anthropic's Claude Fable 5 because of the AI startup's new data retention requirements, The Verge reported on ...
Microsoft’s legal teams are evaluating Anthropic’s new data retention changes. Microsoft’s legal teams are evaluating Anthropic’s new data retention changes. is a senior correspondent and author of ...
Google has completely wiped the quota counters back to zero for all free and paid Gemini users The reset accompanies a new iteration of the Gemini 3.5 Flash to fix sudden drop-offs in output quality ...
shows the logo of Microsoft displayed on the facade of the company France headquarters in Issy-les-Moulineaux, on the outskirts of Paris, on April 24, 2026. Martin LELIEVRE/Getty Images Microsoft ...
Pyrotinib plus nab-paclitaxel as adjuvant therapy for patients with N0/N1mi, HER2-positive early-stage breast cancer: 3-year iDFS results of the phase II PHAEDRA trial. This is an ASCO Meeting ...